世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

細胞治療技術市場：製品別（培地、血清・試薬、細胞培養容器、シングルユース機器）、プロセス別（細胞処理、保存）、細胞タイプ別（T細胞、幹細胞）、エンドユーザー別（バイオファーマ、CRO、CMO）、地域別 - 2028年までの世界予測


Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single-Use Equipment), Process (Cell Processing, Preservation), Cell type (T-Cells, Stem cells), End User (Biopharma, CROs, CMOs), Region - Global Forecast to 2028

世界の細胞治療技術市場規模は、2023年の42億米ドルから2028年には78億米ドルに達すると予測され、予測期間中の年平均成長率は13.3%である。細胞ベースの研究に対する政府投資の増加、慢性疾患や感染症の罹患率の... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2023年7月27日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		236 259 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

世界の細胞治療技術市場規模は、2023年の42億米ドルから2028年には78億米ドルに達すると予測され、予測期間中の年平均成長率は13.3%である。細胞ベースの研究に対する政府投資の増加、慢性疾患や感染症の罹患率の上昇、腫瘍学関連の細胞治療臨床試験の大規模化、細胞治療生産施設のGMP認証取得の増加などの要因が、市場成長にプラスの影響を与えると考えられる。
「細胞治療技術市場ではプロセス分野が圧倒的シェアを占める
世界の細胞治療技術市場は、プロセスに基づき、細胞加工、細胞保存、流通・ハンドリング、プロセスモニタリング・品質管理に区分される。2022年には細胞処理部門が市場で圧倒的なシェアを占めている。細胞加工技術の進歩が市場成長に好影響を与えそうだ。

"バイオ製薬・バイオテクノロジー企業セグメントが2022年の用途別セグメントで最大シェアを占める"
エンドユーザーに基づき、細胞治療技術市場はバイオ医薬品・バイオテクノロジー企業、CROS・CMOS、研究機関・細胞バンクに区分される。2022年には、バイオ医薬品・バイオテクノロジー企業セグメントが細胞治療技術市場で最大のシェアを占めた。同セグメントは、主要市場プレーヤーによる細胞治療製造施設の増加の重視、細胞治療の研究活動への投資の増加などの様々な要因によって、市場で支配的なシェアを占めている。

"アジア太平洋地域はより速いペースで成長する可能性が高い"
細胞治療技術市場は北米、欧州、アジア太平洋、中南米、中東・アフリカに区分される。アジア太平洋地域は予測期間中に大きなCAGRで成長すると予測されている。同地域の成長の主な原動力は、細胞ベースの研究に対する政府投資の増加である。中国、インド、日本では、ワクチン開発のための研究資金が増加し、疾患プロファイルが変化しているため、細胞治療機器や製品に対する需要が増加しており、アジア太平洋地域の市場成長を支えている。さらに、慢性疾患や感染症の罹患率の増加、老人人口の増加、医療インフラ整備のための政府の取り組みなどは、市場成長にプラスの影響を与えると予想される要素の一部である。
本レポートのために実施した一次インタビューは以下のように分類できる：

- 回答者別供給側70％、需要側30
- 回答者の役職別（サプライサイド）マネージャー - 45%、CXOおよびディレクター - 30%、エグゼクティブ - 25
- 地域別北米：40％、欧州：25％、アジア太平洋地域：20％、中南米：10％、中東・アフリカ：5
レポート掲載企業一覧
- サーモフィッシャーサイエンティフィック社（米国）
- Merck KGaA (ドイツ)
- ダナハーコーポレーション（米国）
- ロンザグループ（スイス）
- ザルトリウスAG（ドイツ）
- テルモBCT株式会社（日本）（テルモBCTはテルモ株式会社の一部です）
- ベクトン・ディッキンソン＆カンパニー（米国）
- フレゼニウスSe & co.KGaA（ドイツ）
- Avantor Inc（米国）
- バイオテクネ（米国）
- コーニング・インコーポレイテッド（米）
- 富士フイルムアーバインサイエンティフィック（日本）
- マックスサイト社（米国）
- Werum Software & Systems AG (Korber AGの一部) (ドイツ)
- ルースター・バイオ社（米国）
- シリオン・バイオテック（ドイツ）
- Trakcel社（英国）
- エルセブンインフォマティクス（米国）
- ミルテニ・バイオテック（ドイツ）
- スチームセル・テクノロジーズ（カナダ）
- GPI Iberia (旧ヘマソフト) (スペイン)
- CodexThemes（フランス）
- オルガナビオLLC.米国
- イクセルズ・バイオテクノロジーズ（米国）
- ウィルソンウルフ2019マニュファクチャリングコーポレーション（米国）
調査対象範囲
この調査レポートは、細胞治療技術市場の詳細な姿を掲載しています。製品、プロセス、細胞タイプ、エンドユーザー、地域などの異なるセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの会社概要、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主なメリット
本レポートは、細胞治療技術市場全体とそのサブセグメントについて、最も近似した収益数字を提供することで、市場リーダー／新規参入者を支援します。また、利害関係者が競争状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるのに役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供することを可能にします。
本レポートは、以下のポイントに関する洞察を提供します：
- 主な促進要因（細胞ベースの研究に対する政府投資の増加、慢性疾患および感染症の罹患率の上昇、腫瘍関連の細胞治療臨床試験の大規模化、細胞治療生産施設のGMP認証の増加）、阻害要因（細胞ベースの研究の高コストと低い成功率）の分析、機会（ESCsに代わるiPSCの出現、個別化医療への注目の高まり、細胞療法開発のための官民パートナーシップの増加、アジアの新興市場）、課題（小規模プレイヤーや新規参入企業の生き残り）が細胞療法技術市場の成長に影響を与えている。
- 製品開発/イノベーション：細胞治療技術市場で新たに発売された製品に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的情報 - 当レポートでは、様々な地域における細胞治療技術市場を分析しています。
- 市場の多様化：細胞治療技術市場における新サービス、未開拓の地域、最近の開発、投資に関する詳細な情報。
競合評価：細胞治療技術市場におけるThermo Fisher Scientific, Inc.（米国）、Merck KGaA（ドイツ）、Danaher Corporation（米国）、Becton, Dickinson, and Company（米国）、Lonza Group（スイス）、Sartorius AG（ドイツ）などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価。

ページTOPに戻る


目次

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
1.3.2 YEARS CONSIDERED 34
1.3.3 CURRENCY CONSIDERED 35
1.4 RESEARCH LIMITATIONS 35
1.5 STAKEHOLDERS 35
1.6 SUMMARY OF CHANGES 36
1.7 RECESSION IMPACT 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
FIGURE 1 RESEARCH DESIGN 37
2.1.1 SECONDARY DATA 38
2.1.2 PRIMARY DATA 39
FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES 39
2.2 MARKET SIZE ESTIMATION 40
FIGURE 3 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022 40
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 41
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022 41
2.2.1 INSIGHTS FROM PRIMARIES 43
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 43
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, PROCESS, CELL TYPE, AND END USER) 43
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 43
2.3 GROWTH RATE ASSUMPTIONS 44
FIGURE 8 CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS, 2023–2028 45
FIGURE 9 CELL THERAPY TECHNOLOGIES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 45
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 46
FIGURE 10 DATA TRIANGULATION METHODOLOGY 46
2.5 STUDY ASSUMPTIONS 47
2.6 RISK ANALYSIS 47
2.7 RECESSION IMPACT ANALYSIS 47
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH) 48
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 48
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 48
3 EXECUTIVE SUMMARY 49
FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 49
FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION) 50
FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023 VS. 2028 (USD MILLION) 50
FIGURE 14 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 51
FIGURE 15 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC SNAPSHOT 52
4 PREMIUM INSIGHTS 53
4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW 53
FIGURE 16 INCREASING GOVERNMENT INVESTMENT IN CELL-BASED RESEARCH TO BOOST ADOPTION OF CELL THERAPY TECHNOLOGIES 53
4.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY (2022) 54
FIGURE 17 T CELLS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 54
4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2023 VS. 2028 54
FIGURE 18 MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 2028 54
4.4 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY END USER, 2022 (USD MILLION) 55
FIGURE 19 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES DOMINATED MARKET IN 2022 55
4.5 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 55
FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 21 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
5.2.1 DRIVERS 57
5.2.1.1 Increasing government investments in cell-based research 57
TABLE 4 NIH FUNDING FOR CELL-BASED RESEARCH, 2019–2022 (USD MILLION) 57
5.2.1.2 Rising incidence of chronic and infectious diseases 58
5.2.1.3 Large number of oncology-related cell therapy clinical trials 58
FIGURE 22 CANCER CELL THERAPY PIPELINE, 2021–2022 59
5.2.1.4 Increasing GMP certifications for cell therapy production facilities 59
TABLE 5 EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP 59
5.2.2 RESTRAINTS 60
5.2.2.1 High cost of cell-based research and low success rate 60
TABLE 6 COST OF CELL THERAPY EQUIPMENT 60
5.2.3 OPPORTUNITIES 60
5.2.3.1 Emergence of iPSCs as alternatives to ESCs 60
5.2.3.2 Increased focus on personalized medicine 61
5.2.3.3 Increasing partnerships for development of cell therapies 61
5.2.3.4 Emerging Asian markets 62
5.2.4 CHALLENGES 63
5.2.4.1 Survival of small players and new entrants 63
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 63
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS 63
5.4 INDICATIVE PRICING MODEL ANALYSIS 63
TABLE 7 PRICING ANALYSIS OF CELL THERAPY PRODUCTS 63
5.5 TECHNOLOGY ANALYSIS 64
5.6 VALUE CHAIN ANALYSIS 64
FIGURE 24 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE 65
5.7 SUPPLY CHAIN ANALYSIS 65
FIGURE 25 CELL THERAPY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS 66
5.8 ECOSYSTEM ANALYSIS OF CELL THERAPY TECHNOLOGIES MARKET 67
FIGURE 26 ECOSYSTEM ANALYSIS 67
TABLE 8 SUPPLY CHAIN ECOSYSTEM 67
5.9 KEY CONFERENCES AND EVENTS IN 2022–2023 68
TABLE 9 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 68
5.10 REGULATORY ANALYSIS 69
5.10.1 REGULATORY LANDSCAPE FOR CELL THERAPIES 69
TABLE 10 NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES 69
TABLE 11 EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES 70
TABLE 12 ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES 70
TABLE 13 ROW: REGULATORY LANDSCAPE FOR CELL THERAPIES 72
5.10.2 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
5.11 PORTER’S FIVE FORCES ANALYSIS 76
TABLE 19 CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS 76
5.11.1 THREAT OF NEW ENTRANTS 76
5.11.2 THREAT OF SUBSTITUTES 76
5.11.3 BARGAINING POWER OF SUPPLIERS 76
5.11.4 BARGAINING POWER OF BUYERS 76
5.11.5 DEGREE OF COMPETITION 76
5.12 PATENT ANALYSIS 77
FIGURE 27 PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JULY 2013–JULY 2023 77
TABLE 20 CELL THERAPY TECHNOLOGIES MARKET: INDICATIVE LIST OF PATENTS 78
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 79
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CELL THERAPY PRODUCTS 79
5.13.2 BUYING CRITERIA FOR CELL THERAPY PRODUCTS 80
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 80
6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT 81
6.1 INTRODUCTION 82
TABLE 21 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 82
6.2 MEDIA, SERA, AND REAGENTS 82
6.2.1 IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET 82
TABLE 22 MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 23 NORTH AMERICA: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 24 EUROPE: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 25 ASIA PACIFIC: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
6.3 CELL ENGINEERING PRODUCTS 85
6.3.1 AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH 85
TABLE 26 CELL ENGINEERING PRODUCTS OFFERED, BY COMPANY 85
TABLE 27 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 85
TABLE 28 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 29 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 30 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
6.4 CELL CULTURE VESSELS 87
6.4.1 WIDE USAGE OF CELL CULTURE VESSELS IN CELL GROWTH APPLICATIONS 87
TABLE 31 CELL CULTURE VESSELS MARKET, BY REGION, 2021–2028 (USD MILLION) 87
TABLE 32 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 33 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 34 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
6.5 CELL THERAPY EQUIPMENT 88
TABLE 35 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 89
TABLE 36 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 37 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, 2021–2028 (USD MILLION) 90
TABLE 38 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 39 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
6.5.1 CELL PROCESSING EQUIPMENT 91
6.5.1.1 Cell processing equipment to dominate market 91
TABLE 40 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 41 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 42 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 43 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
6.5.2 SINGLE-USE EQUIPMENT 93
6.5.2.1 Benefits of single-use equipment to ensure end-user demand 93
TABLE 44 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION) 93
TABLE 45 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 46 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 47 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
6.5.3 OTHER EQUIPMENT 94
TABLE 48 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION) 95
TABLE 49 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 50 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 51 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
6.6 SYSTEMS & SOFTWARE 96
6.6.1 NEED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING TO DRIVE DEMAND 96
TABLE 52 SYSTEMS & SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 53 NORTH AMERICA: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 54 EUROPE: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 55 ASIA PACIFIC: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
6.7 OTHER PRODUCTS 98
TABLE 56 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 57 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 58 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 59 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS 100
7.1 INTRODUCTION 101
TABLE 60 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 101
7.2 CELL PROCESSING 101
7.2.1 CELL PROCESSING TO HOLD LARGEST MARKET SHARE TILL 2028 101
TABLE 61 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 62 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 63 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 64 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION) 103
7.3 CELL PRESERVATION, DISTRIBUTION, AND HANDLING 103
7.3.1 INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH 103
TABLE 65 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 66 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 67 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 68 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION) 105
7.4 PROCESS MONITORING & QUALITY CONTROL 105
7.4.1 NEED TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING TO BOOST ADOPTION 105
TABLE 69 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 70 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 71 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 72 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION) 107
8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE 108
8.1 INTRODUCTION 109
TABLE 73 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 109
8.2 T CELLS 109
8.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH 109
TABLE 74 CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY REGION, 2021–2028 (USD MILLION) 110
TABLE 75 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 76 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 77 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 111
8.3 STEM CELLS 112
8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET 112
TABLE 78 CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY REGION, 2021–2028 (USD MILLION) 112
TABLE 79 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 80 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 81 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 113
8.4 OTHER CELLS 114
TABLE 82 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 83 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 84 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 85 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 115
 
9 CELL THERAPY TECHNOLOGIES MARKET, BY END USER 116
9.1 INTRODUCTION 117
TABLE 86 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 117
9.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 117
9.2.1 GROWING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE MARKET 117
TABLE 87 CELL THERAPY TECHNOLOGIES MARKET & BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 88 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 89 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 90 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 119
9.3 CROS & CMOS 119
9.3.1 FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH 119
TABLE 91 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 92 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 93 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 94 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION) 121
9.4 RESEARCH INSTITUTES & CELL BANKS 121
9.4.1 RISING RESEARCH ACTIVITY TO SUPPORT MARKET GROWTH 121
TABLE 95 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY REGION, 2021–2028 (USD MILLION) 122
TABLE 96 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 97 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 98 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION) 123
10 CELL THERAPY TECHNOLOGIES MARKET, BY REGION 124
10.1 INTRODUCTION 125
TABLE 99 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION) 125
10.2 NORTH AMERICA 125
10.2.1 NORTH AMERICA: RECESSION IMPACT 125
FIGURE 30 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 126
TABLE 100 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 101 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 127
TABLE 102 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 103 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 128
TABLE 104 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 128
TABLE 105 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 128
10.2.2 US 129
10.2.2.1 Increasing R&D activities to support market growth 129
TABLE 106 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 129
TABLE 107 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 108 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 130
TABLE 109 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 130
TABLE 110 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 130
10.2.3 CANADA 131
10.2.3.1 Increasing government funding to drive adoption of cell therapy instruments 131
TABLE 111 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 131
TABLE 112 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 113 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 132
TABLE 114 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 132
TABLE 115 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 133
10.3 EUROPE 133
10.3.1 EUROPE: RECESSION IMPACT 133
TABLE 116 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 117 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 134
TABLE 118 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 119 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 135
TABLE 120 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 135
TABLE 121 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 136
10.3.2 GERMANY 136
10.3.2.1 Germany to hold largest share of European market 136
TABLE 122 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 137
TABLE 123 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 124 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 138
TABLE 125 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 138
TABLE 126 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 138
10.3.3 UK 139
10.3.3.1 Favorable funding and investment scenario to drive market 139
TABLE 127 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 139
TABLE 128 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 129 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 140
TABLE 130 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 140
TABLE 131 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 140
10.3.4 FRANCE 141
10.3.4.1 Availability of government and private support to drive market 141
TABLE 132 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 141
TABLE 133 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 134 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 142
TABLE 135 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 142
TABLE 136 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 142
10.3.5 ITALY 143
10.3.5.1 Initiatives favoring cell and gene therapy development to support market growth 143
TABLE 137 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 143
TABLE 138 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 139 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 144
TABLE 140 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 144
TABLE 141 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 144
10.3.6 SPAIN 145
10.3.6.1 Increasing funding from private and public organizations to aid market growth 145
TABLE 142 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 145
TABLE 143 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 144 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 146
TABLE 145 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 146
TABLE 146 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 146
10.3.7 REST OF EUROPE 147
TABLE 147 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 147
TABLE 148 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 149 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 148
TABLE 150 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 148
TABLE 151 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 148
10.4 ASIA PACIFIC 149
FIGURE 31 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 149
10.4.1 ASIA PACIFIC: RECESSION IMPACT 150
TABLE 152 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 153 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 151
TABLE 154 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 155 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 152
TABLE 156 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 152
TABLE 157 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 152
10.4.2 CHINA 153
10.4.2.1 Increasing cell therapy-based trials to support market growth 153
TABLE 158 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 153
TABLE 159 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 160 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 154
TABLE 161 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 154
TABLE 162 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 155
10.4.3 JAPAN 155
10.4.3.1 Rising geriatric population and growing disease prevalence to drive market 155
TABLE 163 JAPAN: CANCER INCIDENCE IN MALES VS FEMALES, BY TYPE, 2022 156
TABLE 164 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 156
TABLE 165 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 166 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 157
TABLE 167 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 157
TABLE 168 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 158
10.4.4 INDIA 158
10.4.4.1 Favorable government regulations to support market growth 158
TABLE 169 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 159
TABLE 170 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 171 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 160
TABLE 172 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 160
TABLE 173 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 160
10.4.5 REST OF ASIA PACIFIC 161
TABLE 174 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 161
TABLE 175 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 176 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 162
TABLE 177 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 162
TABLE 178 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 162
10.5 LATIN AMERICA 163
10.5.1 AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET 163
10.5.2 LATIN AMERICA: RECESSION IMPACT 163
TABLE 179 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 164
TABLE 180 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 181 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 165
TABLE 182 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 165
TABLE 183 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 165
10.6 MIDDLE EAST & AFRICA 166
10.6.1 INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET 166
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 166
TABLE 184 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 167
TABLE 185 MIDDLE EAST & AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 186 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 168
TABLE 187 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 168
TABLE 188 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 168
11 COMPETITIVE LANDSCAPE 169
11.1 INTRODUCTION 169
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 170
FIGURE 32 CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 170
11.3 REVENUE SHARE ANALYSIS 171
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022 171
11.4 MARKET SHARE ANALYSIS 171
FIGURE 34 CELL THERAPY TECHNOLOGIES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022 172
TABLE 189 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION 172
11.5 COMPANY EVALUATION MATRIX, 2022 173
11.5.1 STARS 174
11.5.2 EMERGING LEADERS 174
11.5.3 PERVASIVE PLAYERS 174
11.5.4 PARTICIPANTS 174
FIGURE 35 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 175
11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 176
11.6.1 COMPANY PRODUCT FOOTPRINT (25 COMPANIES) 176
TABLE 190 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS 176
11.6.2 COMPANY PROCESS FOOTPRINT (25 COMPANIES) 177
TABLE 191 PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS 177
11.6.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES) 178
TABLE 192 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS 178
11.7 COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 179
11.7.1 PROGRESSIVE COMPANIES 179
11.7.2 STARTING BLOCKS 179
11.7.3 RESPONSIVE COMPANIES 179
11.7.4 DYNAMIC COMPANIES 179
FIGURE 36 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 180
11.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 181
TABLE 193 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 181
TABLE 194 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS 182
11.9 COMPETITIVE SCENARIO AND TRENDS 183
11.9.1 PRODUCT LAUNCHES 183
TABLE 195 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2020–APRIL 2023 183
11.9.2 DEALS 184
TABLE 196 CELL THERAPY TECHNOLOGIES MARKET: DEALS, JANUARY 2020–APRIL 2023 184
11.9.3 OTHER DEVELOPMENTS 185
TABLE 197 CELL THERAPY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS, JANUARY 2020–APRIL 2023 185
12 COMPANY PROFILES 186
12.1 KEY MARKET PLAYERS 186
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 THERMO FISHER SCIENTIFIC, INC. 186
TABLE 198 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 186
FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 187
12.1.2 MERCK KGAA 191
TABLE 199 MERCK KGAA: BUSINESS OVERVIEW 191
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2022) 192
12.1.3 DANAHER CORPORATION 195
TABLE 200 DANAHER CORPORATION: BUSINESS OVERVIEW 195
FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 196
12.1.4 LONZA GROUP 200
TABLE 201 LONZA GROUP: BUSINESS OVERVIEW 200
FIGURE 40 LONZA GROUP: COMPANY SNAPSHOT (2022) 201
12.1.5 SARTORIUS AG 203
TABLE 202 SARTORIUS AG: BUSINESS OVERVIEW 203
FIGURE 41 SARTORIUS AG: COMPANY SNAPSHOT (2022) 204
12.1.6 TERUMO BCT, INC. 206
TABLE 203 TERUMO BCT, INC: BUSINESS OVERVIEW 206
FIGURE 42 TERUMO BCT, INC.: COMPANY SNAPSHOT (2022) 207
12.1.7 BECTON DICKINSON AND COMPANY 209
TABLE 204 BECTON DICKINSON AND COMPANY: BUSINESS OVERVIEW 209
FIGURE 43 BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 210
12.1.8 FRESENIUS SE & CO. KGAA 212
TABLE 205 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW 212
FIGURE 44 FRESENIUS SE & CO: COMPANY SNAPSHOT (2022) 213
12.1.9 AVANTOR, INC. 215
TABLE 206 AVANTOR, INC.: BUSINESS OVERVIEW 215
FIGURE 45 AVANTOR, INC.: COMPANY SNAPSHOT (2022) 215
12.1.10 BIO-TECHNE 218
TABLE 207 BIO-TECHNE: BUSINESS OVERVIEW 218
FIGURE 46 BIO-TECHNE: COMPANY SNAPSHOT (2022) 219
12.1.11 CORNING INCORPORATED 221
TABLE 208 CORNING INCORPORATED: BUSINESS OVERVIEW 221
FIGURE 47 CORNING INCORPORATED: COMPANY SNAPSHOT (2022) 222
12.1.12 FUJIFILM IRVINE SCIENTIFIC 223
TABLE 209 FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW 223
FIGURE 48 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT (2022) 224
12.1.13 MAXCYTE, INC. 226
TABLE 210 MAXCYTE, INC.: BUSINESS OVERVIEW 226
FIGURE 49 MAXCYTE, INC.: COMPANY SNAPSHOT (2022) 226
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 228
12.2.1 WERUM IT SOLUTIONS 228
12.2.2 ROOSTERBIO, INC. 229
12.2.3 SIRION BIOTECH 230
12.2.4 TRAKCEL 230
12.2.5 L7 INFORMATICS, INC. 231
12.2.6 MILTENYI BIOTEC B.V. & CO. KG 231
12.2.7 STEMCELL TECHNOLOGIES 233
12.2.8 GPI IBERIA (FORMERLY HEMASOFT) 234
12.2.9 MAK-SYSTEM 235
12.2.10 ORGANABIO 235
12.2.11 IXCELLS BIOTECHNOLOGIES 236
12.2.12 WILSON WOLF 236
 
13 APPENDIX 237
13.1 DISCUSSION GUIDE 237
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 241
13.3 CUSTOMIZATION OPTIONS 243
13.4 RELATED REPORTS 243
13.5 AUTHOR DETAILS 244

　

ページTOPに戻る


　

Summary

The global cell therapy technologies market size is projected to reach USD 7.8 billion by 2028 from USD 4.2 billion in 2023, at a CAGR of 13.3 % during the forecast period. Factors such as increasing government investments in cell-based research, rising incidence of chronic and infectious diseases, large no of oncology related cell therapy clinical trials, increasing GMP certification for cell therapy production facilities are likely to have positive impact on the market growth.
“The process segment held the dominant share in the cell therapy technologies market”
Based on process, the global cell therapy technologies market is segmented into cell processing, cell preservation, distribution & handling, process monitoring & quality control. The cell processing segment held a dominant share in the market in 2022. Advancement in cell processing techniques is likely to have positive impact on the growth of the market.

“Biopharmaceutical and biotechnology companies segment accounted for the largest share of the application segment in 2022.”
Based on end users, the cell therapy technologies market is segmented into biopharmaceutical & biotechnology companies, CROS & CMOS, research institutes & cell banks. In 2022, the biopharmaceutical and biotechnology companies segment accounted for the largest share of the cell therapy technologies market. The segment held the dominant share in the market owing to various factors such as the emphasis on increase in number of cell therapy manufacturing facilities by key market players and rising investment in research activities of cell therapy.

“Asia Pacific region is likely to grow at a faster pace.”
The cell therapy technologies market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by the increasing government investments in cell-based research. The increasing demand for cell therapy instruments and products from China, India, and Japan due to the rising research funding for vaccine development and changing disease profiles supports market growth in the Asia Pacific. Furthermore, increasing incidence of chronic and infectious diseases, the rising geriatric population, and government initiatives for healthcare infrastructural improvements are some of the elements anticipated to account for positive impact on the market growth.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70%, and Demand Side - 30%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
List of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• Danaher Corporation (US)
• Lonza Group (Switzerland)
• Sartorius AG(Germany)
• Terumo Bct, Inc Corporation (Japan) (Terumo BCT is part of Terumo Corporation)
• Becton, Dickinson & Company (US)
• Fresenius Se & co. KGaA (Germany)
• Avantor Inc (US)
• Bio-Techne (US)
• Corning Incorporated (US)
• Fujifilm Irvine Scientific (Japan)
• Maxcyte Inc. (US)
• Werum Software & Systems AG (Part of Korber AG) (Germany)
• Roosterbio Inc. (US)
• Sirion Biotech Gmbh (Germany)
• Trakcel (UK)
• L 7 Informatics Inc. (US)
• Miltenyi Biotech (Germany)
• Steamcell Technologies Inc. (Canada)
• GPI Iberia (Formerly Hemasoft) (Spain)
• CodexThemes (France)
• Organabio LLC. (US)
• Ixcells Biotechnologies (US)
• Wilson Wolf 2019 Manufacturing Corporation (US)
Research Coverage:
This report provides a detailed picture of the cell therapy technologies market. It aims at estimating the size and future growth potential of the market across different segments, such as product, process,cell type, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Increasing government investments in cell-based research, Rising incidence of chronic and infectious diseases, large no of oncology related cell therapy clinical trials, Increasing GMP certification for cell therapy production facilities), restraints ( High cost of cell-based research and low success rate), opportunities (Emergence of iPSC as alternatives to ESCs, Increased focus on personalized medicine, Increasing public-private partnerships for development of cell therapies, Emerging Asian markets), and challenges (Survival for small players and new entrants)are influencing the growth of cell therapy technologies market.
• Product Development/Innovation: Detailed insights on newly launched products of the cell therapy technologies market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the Cell therapy technologies market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the cell therapy technologies market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Becton, Dickinson, and Company (US), Lonza Group (Switzerland), Sartorius AG (Germany), and among others in the cell therapy technologies market.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
1.3.2 YEARS CONSIDERED 34
1.3.3 CURRENCY CONSIDERED 35
1.4 RESEARCH LIMITATIONS 35
1.5 STAKEHOLDERS 35
1.6 SUMMARY OF CHANGES 36
1.7 RECESSION IMPACT 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
FIGURE 1 RESEARCH DESIGN 37
2.1.1 SECONDARY DATA 38
2.1.2 PRIMARY DATA 39
FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES 39
2.2 MARKET SIZE ESTIMATION 40
FIGURE 3 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022 40
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 41
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022 41
2.2.1 INSIGHTS FROM PRIMARIES 43
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 43
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, PROCESS, CELL TYPE, AND END USER) 43
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 43
2.3 GROWTH RATE ASSUMPTIONS 44
FIGURE 8 CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS, 2023–2028 45
FIGURE 9 CELL THERAPY TECHNOLOGIES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 45
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 46
FIGURE 10 DATA TRIANGULATION METHODOLOGY 46
2.5 STUDY ASSUMPTIONS 47
2.6 RISK ANALYSIS 47
2.7 RECESSION IMPACT ANALYSIS 47
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH) 48
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 48
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 48
3 EXECUTIVE SUMMARY 49
FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 49
FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION) 50
FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023 VS. 2028 (USD MILLION) 50
FIGURE 14 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 51
FIGURE 15 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC SNAPSHOT 52
4 PREMIUM INSIGHTS 53
4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW 53
FIGURE 16 INCREASING GOVERNMENT INVESTMENT IN CELL-BASED RESEARCH TO BOOST ADOPTION OF CELL THERAPY TECHNOLOGIES 53
4.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY (2022) 54
FIGURE 17 T CELLS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 54
4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2023 VS. 2028 54
FIGURE 18 MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 2028 54
4.4 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY END USER, 2022 (USD MILLION) 55
FIGURE 19 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES DOMINATED MARKET IN 2022 55
4.5 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 55
FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 21 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
5.2.1 DRIVERS 57
5.2.1.1 Increasing government investments in cell-based research 57
TABLE 4 NIH FUNDING FOR CELL-BASED RESEARCH, 2019–2022 (USD MILLION) 57
5.2.1.2 Rising incidence of chronic and infectious diseases 58
5.2.1.3 Large number of oncology-related cell therapy clinical trials 58
FIGURE 22 CANCER CELL THERAPY PIPELINE, 2021–2022 59
5.2.1.4 Increasing GMP certifications for cell therapy production facilities 59
TABLE 5 EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP 59
5.2.2 RESTRAINTS 60
5.2.2.1 High cost of cell-based research and low success rate 60
TABLE 6 COST OF CELL THERAPY EQUIPMENT 60
5.2.3 OPPORTUNITIES 60
5.2.3.1 Emergence of iPSCs as alternatives to ESCs 60
5.2.3.2 Increased focus on personalized medicine 61
5.2.3.3 Increasing partnerships for development of cell therapies 61
5.2.3.4 Emerging Asian markets 62
5.2.4 CHALLENGES 63
5.2.4.1 Survival of small players and new entrants 63
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 63
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS 63
5.4 INDICATIVE PRICING MODEL ANALYSIS 63
TABLE 7 PRICING ANALYSIS OF CELL THERAPY PRODUCTS 63
5.5 TECHNOLOGY ANALYSIS 64
5.6 VALUE CHAIN ANALYSIS 64
FIGURE 24 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE 65
5.7 SUPPLY CHAIN ANALYSIS 65
FIGURE 25 CELL THERAPY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS 66
5.8 ECOSYSTEM ANALYSIS OF CELL THERAPY TECHNOLOGIES MARKET 67
FIGURE 26 ECOSYSTEM ANALYSIS 67
TABLE 8 SUPPLY CHAIN ECOSYSTEM 67
5.9 KEY CONFERENCES AND EVENTS IN 2022–2023 68
TABLE 9 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 68
5.10 REGULATORY ANALYSIS 69
5.10.1 REGULATORY LANDSCAPE FOR CELL THERAPIES 69
TABLE 10 NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES 69
TABLE 11 EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES 70
TABLE 12 ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES 70
TABLE 13 ROW: REGULATORY LANDSCAPE FOR CELL THERAPIES 72
5.10.2 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
5.11 PORTER’S FIVE FORCES ANALYSIS 76
TABLE 19 CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS 76
5.11.1 THREAT OF NEW ENTRANTS 76
5.11.2 THREAT OF SUBSTITUTES 76
5.11.3 BARGAINING POWER OF SUPPLIERS 76
5.11.4 BARGAINING POWER OF BUYERS 76
5.11.5 DEGREE OF COMPETITION 76
5.12 PATENT ANALYSIS 77
FIGURE 27 PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JULY 2013–JULY 2023 77
TABLE 20 CELL THERAPY TECHNOLOGIES MARKET: INDICATIVE LIST OF PATENTS 78
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 79
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CELL THERAPY PRODUCTS 79
5.13.2 BUYING CRITERIA FOR CELL THERAPY PRODUCTS 80
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 80
6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT 81
6.1 INTRODUCTION 82
TABLE 21 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 82
6.2 MEDIA, SERA, AND REAGENTS 82
6.2.1 IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET 82
TABLE 22 MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 23 NORTH AMERICA: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 24 EUROPE: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 25 ASIA PACIFIC: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
6.3 CELL ENGINEERING PRODUCTS 85
6.3.1 AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH 85
TABLE 26 CELL ENGINEERING PRODUCTS OFFERED, BY COMPANY 85
TABLE 27 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 85
TABLE 28 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 29 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 30 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
6.4 CELL CULTURE VESSELS 87
6.4.1 WIDE USAGE OF CELL CULTURE VESSELS IN CELL GROWTH APPLICATIONS 87
TABLE 31 CELL CULTURE VESSELS MARKET, BY REGION, 2021–2028 (USD MILLION) 87
TABLE 32 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 33 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 34 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
6.5 CELL THERAPY EQUIPMENT 88
TABLE 35 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 89
TABLE 36 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 37 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, 2021–2028 (USD MILLION) 90
TABLE 38 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 39 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
6.5.1 CELL PROCESSING EQUIPMENT 91
6.5.1.1 Cell processing equipment to dominate market 91
TABLE 40 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 41 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 42 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 43 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
6.5.2 SINGLE-USE EQUIPMENT 93
6.5.2.1 Benefits of single-use equipment to ensure end-user demand 93
TABLE 44 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION) 93
TABLE 45 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 46 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 47 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
6.5.3 OTHER EQUIPMENT 94
TABLE 48 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION) 95
TABLE 49 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 50 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 51 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
6.6 SYSTEMS & SOFTWARE 96
6.6.1 NEED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING TO DRIVE DEMAND 96
TABLE 52 SYSTEMS & SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 53 NORTH AMERICA: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 54 EUROPE: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 55 ASIA PACIFIC: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
6.7 OTHER PRODUCTS 98
TABLE 56 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 57 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 58 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 59 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS 100
7.1 INTRODUCTION 101
TABLE 60 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 101
7.2 CELL PROCESSING 101
7.2.1 CELL PROCESSING TO HOLD LARGEST MARKET SHARE TILL 2028 101
TABLE 61 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 62 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 63 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 64 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION) 103
7.3 CELL PRESERVATION, DISTRIBUTION, AND HANDLING 103
7.3.1 INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH 103
TABLE 65 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 66 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 67 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 68 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION) 105
7.4 PROCESS MONITORING & QUALITY CONTROL 105
7.4.1 NEED TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING TO BOOST ADOPTION 105
TABLE 69 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 70 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 71 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 72 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION) 107
8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE 108
8.1 INTRODUCTION 109
TABLE 73 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 109
8.2 T CELLS 109
8.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH 109
TABLE 74 CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY REGION, 2021–2028 (USD MILLION) 110
TABLE 75 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 76 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 77 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 111
8.3 STEM CELLS 112
8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET 112
TABLE 78 CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY REGION, 2021–2028 (USD MILLION) 112
TABLE 79 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 80 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 81 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 113
8.4 OTHER CELLS 114
TABLE 82 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 83 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 84 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 85 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 115
 
9 CELL THERAPY TECHNOLOGIES MARKET, BY END USER 116
9.1 INTRODUCTION 117
TABLE 86 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 117
9.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 117
9.2.1 GROWING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE MARKET 117
TABLE 87 CELL THERAPY TECHNOLOGIES MARKET & BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 88 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 89 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 90 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 119
9.3 CROS & CMOS 119
9.3.1 FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH 119
TABLE 91 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 92 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 93 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 94 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION) 121
9.4 RESEARCH INSTITUTES & CELL BANKS 121
9.4.1 RISING RESEARCH ACTIVITY TO SUPPORT MARKET GROWTH 121
TABLE 95 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY REGION, 2021–2028 (USD MILLION) 122
TABLE 96 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 97 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 98 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION) 123
10 CELL THERAPY TECHNOLOGIES MARKET, BY REGION 124
10.1 INTRODUCTION 125
TABLE 99 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION) 125
10.2 NORTH AMERICA 125
10.2.1 NORTH AMERICA: RECESSION IMPACT 125
FIGURE 30 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 126
TABLE 100 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 101 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 127
TABLE 102 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 103 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 128
TABLE 104 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 128
TABLE 105 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 128
10.2.2 US 129
10.2.2.1 Increasing R&D activities to support market growth 129
TABLE 106 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 129
TABLE 107 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 108 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 130
TABLE 109 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 130
TABLE 110 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 130
10.2.3 CANADA 131
10.2.3.1 Increasing government funding to drive adoption of cell therapy instruments 131
TABLE 111 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 131
TABLE 112 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 113 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 132
TABLE 114 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 132
TABLE 115 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 133
10.3 EUROPE 133
10.3.1 EUROPE: RECESSION IMPACT 133
TABLE 116 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 117 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 134
TABLE 118 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 119 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 135
TABLE 120 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 135
TABLE 121 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 136
10.3.2 GERMANY 136
10.3.2.1 Germany to hold largest share of European market 136
TABLE 122 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 137
TABLE 123 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 124 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 138
TABLE 125 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 138
TABLE 126 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 138
10.3.3 UK 139
10.3.3.1 Favorable funding and investment scenario to drive market 139
TABLE 127 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 139
TABLE 128 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 129 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 140
TABLE 130 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 140
TABLE 131 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 140
10.3.4 FRANCE 141
10.3.4.1 Availability of government and private support to drive market 141
TABLE 132 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 141
TABLE 133 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 134 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 142
TABLE 135 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 142
TABLE 136 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 142
10.3.5 ITALY 143
10.3.5.1 Initiatives favoring cell and gene therapy development to support market growth 143
TABLE 137 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 143
TABLE 138 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 139 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 144
TABLE 140 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 144
TABLE 141 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 144
10.3.6 SPAIN 145
10.3.6.1 Increasing funding from private and public organizations to aid market growth 145
TABLE 142 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 145
TABLE 143 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 144 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 146
TABLE 145 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 146
TABLE 146 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 146
10.3.7 REST OF EUROPE 147
TABLE 147 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 147
TABLE 148 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 149 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 148
TABLE 150 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 148
TABLE 151 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 148
10.4 ASIA PACIFIC 149
FIGURE 31 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 149
10.4.1 ASIA PACIFIC: RECESSION IMPACT 150
TABLE 152 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 153 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 151
TABLE 154 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 155 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 152
TABLE 156 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 152
TABLE 157 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 152
10.4.2 CHINA 153
10.4.2.1 Increasing cell therapy-based trials to support market growth 153
TABLE 158 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 153
TABLE 159 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 160 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 154
TABLE 161 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 154
TABLE 162 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 155
10.4.3 JAPAN 155
10.4.3.1 Rising geriatric population and growing disease prevalence to drive market 155
TABLE 163 JAPAN: CANCER INCIDENCE IN MALES VS FEMALES, BY TYPE, 2022 156
TABLE 164 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 156
TABLE 165 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 166 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 157
TABLE 167 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 157
TABLE 168 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 158
10.4.4 INDIA 158
10.4.4.1 Favorable government regulations to support market growth 158
TABLE 169 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 159
TABLE 170 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 171 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 160
TABLE 172 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 160
TABLE 173 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 160
10.4.5 REST OF ASIA PACIFIC 161
TABLE 174 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 161
TABLE 175 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 176 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 162
TABLE 177 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 162
TABLE 178 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 162
10.5 LATIN AMERICA 163
10.5.1 AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET 163
10.5.2 LATIN AMERICA: RECESSION IMPACT 163
TABLE 179 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 164
TABLE 180 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 181 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 165
TABLE 182 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 165
TABLE 183 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 165
10.6 MIDDLE EAST & AFRICA 166
10.6.1 INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET 166
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 166
TABLE 184 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 167
TABLE 185 MIDDLE EAST & AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 186 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 168
TABLE 187 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021–2028 (USD MILLION) 168
TABLE 188 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021–2028 (USD MILLION) 168
11 COMPETITIVE LANDSCAPE 169
11.1 INTRODUCTION 169
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 170
FIGURE 32 CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 170
11.3 REVENUE SHARE ANALYSIS 171
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022 171
11.4 MARKET SHARE ANALYSIS 171
FIGURE 34 CELL THERAPY TECHNOLOGIES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022 172
TABLE 189 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION 172
11.5 COMPANY EVALUATION MATRIX, 2022 173
11.5.1 STARS 174
11.5.2 EMERGING LEADERS 174
11.5.3 PERVASIVE PLAYERS 174
11.5.4 PARTICIPANTS 174
FIGURE 35 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 175
11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 176
11.6.1 COMPANY PRODUCT FOOTPRINT (25 COMPANIES) 176
TABLE 190 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS 176
11.6.2 COMPANY PROCESS FOOTPRINT (25 COMPANIES) 177
TABLE 191 PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS 177
11.6.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES) 178
TABLE 192 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS 178
11.7 COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 179
11.7.1 PROGRESSIVE COMPANIES 179
11.7.2 STARTING BLOCKS 179
11.7.3 RESPONSIVE COMPANIES 179
11.7.4 DYNAMIC COMPANIES 179
FIGURE 36 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 180
11.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 181
TABLE 193 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 181
TABLE 194 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS 182
11.9 COMPETITIVE SCENARIO AND TRENDS 183
11.9.1 PRODUCT LAUNCHES 183
TABLE 195 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2020–APRIL 2023 183
11.9.2 DEALS 184
TABLE 196 CELL THERAPY TECHNOLOGIES MARKET: DEALS, JANUARY 2020–APRIL 2023 184
11.9.3 OTHER DEVELOPMENTS 185
TABLE 197 CELL THERAPY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS, JANUARY 2020–APRIL 2023 185
12 COMPANY PROFILES 186
12.1 KEY MARKET PLAYERS 186
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 THERMO FISHER SCIENTIFIC, INC. 186
TABLE 198 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 186
FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 187
12.1.2 MERCK KGAA 191
TABLE 199 MERCK KGAA: BUSINESS OVERVIEW 191
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2022) 192
12.1.3 DANAHER CORPORATION 195
TABLE 200 DANAHER CORPORATION: BUSINESS OVERVIEW 195
FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 196
12.1.4 LONZA GROUP 200
TABLE 201 LONZA GROUP: BUSINESS OVERVIEW 200
FIGURE 40 LONZA GROUP: COMPANY SNAPSHOT (2022) 201
12.1.5 SARTORIUS AG 203
TABLE 202 SARTORIUS AG: BUSINESS OVERVIEW 203
FIGURE 41 SARTORIUS AG: COMPANY SNAPSHOT (2022) 204
12.1.6 TERUMO BCT, INC. 206
TABLE 203 TERUMO BCT, INC: BUSINESS OVERVIEW 206
FIGURE 42 TERUMO BCT, INC.: COMPANY SNAPSHOT (2022) 207
12.1.7 BECTON DICKINSON AND COMPANY 209
TABLE 204 BECTON DICKINSON AND COMPANY: BUSINESS OVERVIEW 209
FIGURE 43 BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 210
12.1.8 FRESENIUS SE & CO. KGAA 212
TABLE 205 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW 212
FIGURE 44 FRESENIUS SE & CO: COMPANY SNAPSHOT (2022) 213
12.1.9 AVANTOR, INC. 215
TABLE 206 AVANTOR, INC.: BUSINESS OVERVIEW 215
FIGURE 45 AVANTOR, INC.: COMPANY SNAPSHOT (2022) 215
12.1.10 BIO-TECHNE 218
TABLE 207 BIO-TECHNE: BUSINESS OVERVIEW 218
FIGURE 46 BIO-TECHNE: COMPANY SNAPSHOT (2022) 219
12.1.11 CORNING INCORPORATED 221
TABLE 208 CORNING INCORPORATED: BUSINESS OVERVIEW 221
FIGURE 47 CORNING INCORPORATED: COMPANY SNAPSHOT (2022) 222
12.1.12 FUJIFILM IRVINE SCIENTIFIC 223
TABLE 209 FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW 223
FIGURE 48 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT (2022) 224
12.1.13 MAXCYTE, INC. 226
TABLE 210 MAXCYTE, INC.: BUSINESS OVERVIEW 226
FIGURE 49 MAXCYTE, INC.: COMPANY SNAPSHOT (2022) 226
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 228
12.2.1 WERUM IT SOLUTIONS 228
12.2.2 ROOSTERBIO, INC. 229
12.2.3 SIRION BIOTECH 230
12.2.4 TRAKCEL 230
12.2.5 L7 INFORMATICS, INC. 231
12.2.6 MILTENYI BIOTEC B.V. & CO. KG 231
12.2.7 STEMCELL TECHNOLOGIES 233
12.2.8 GPI IBERIA (FORMERLY HEMASOFT) 234
12.2.9 MAK-SYSTEM 235
12.2.10 ORGANABIO 235
12.2.11 IXCELLS BIOTECHNOLOGIES 236
12.2.12 WILSON WOLF 236
 
13 APPENDIX 237
13.1 DISCUSSION GUIDE 237
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 241
13.3 CUSTOMIZATION OPTIONS 243
13.4 RELATED REPORTS 243
13.5 AUTHOR DETAILS 244

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（cell therapy）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/12/23　10:26

157.72 円

164.94 円

201.11 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.